Literature DB >> 27862903

Efficacy of Dexmedetomidine as a Sole Sedative Agent in Small Diagnostic and Therapeutic Procedures: A Systematic Review.

Feline F J A Ter Bruggen1, Ismail Eralp1, Chris K Jansen1, Dirk L Stronks1, Frank J P M Huygen1.   

Abstract

Dexmedetomidine is an upcoming agent with sedative, anxiolytic, and analgesic properties. This review summarizes empirical evidence for the efficacy of dexmedetomidine as a sole sedative agent, and its effectiveness for small diagnostic and therapeutic procedure, in comparison with other frequently used sedatives. All randomized controlled trials on the effect of dexmedetomidine were reviewed. Pain level, patient satisfaction, operator satisfaction, procedure duration, recovery time, and hemodynamic and respiratory characteristics were examined. A total of 1993 patients (1,621 adults; 372 children) from 35 studies were included. In the adult studies, dexmedetomidine yielded significantly lower pain levels compared to the other sedatives (in 31.25% of the included studies) and significantly more patient satisfaction (68.2%). In studies on children, more favorable results concerning respiratory safety and the level of adequate sedation were found compared to the control sedatives. Implications for future studies are discussed.
© 2016 World Institute of Pain.

Entities:  

Keywords:  analgesia; anesthesia; conscious sedation; sedatives

Mesh:

Substances:

Year:  2016        PMID: 27862903     DOI: 10.1111/papr.12519

Source DB:  PubMed          Journal:  Pain Pract        ISSN: 1530-7085            Impact factor:   3.183


  1 in total

1.  Adaptive randomised controlled non-inferiority multicentre trial (the Ketodex Trial) on intranasal dexmedetomidine plus ketamine for procedural sedation in children: study protocol.

Authors:  Naveen Poonai; Kamary Coriolano; Terry Klassen; Anna Heath; Maryna Yaskina; Darcy Beer; Scott Sawyer; Maala Bhatt; April Kam; Quynh Doan; Vikram Sabhaney; Martin Offringa; Petros Pechlivanoglou; Serena Hickes; Samina Ali
Journal:  BMJ Open       Date:  2020-12-10       Impact factor: 2.692

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.